Transformation into a Global Biopharmaceutical Company Through a Second Founding Phase
A theme centered on positioning the fiscal year ending December 2026 as a second founding phase and advancing the transformation into a global biopharmaceutical company through M&A and corporate restructuring.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.